Polymorphic CYP substrates within the ISS drug list: Information about involvement of polymorphic drug metabolism from the drug labels or from evidence-based pharmacogenetic guidelines.

* Level of evidence: 1: in vitro data only, 2: in vivo pk data, 3: clinical data on efficacy and/or side effectsAmong the drugs listed in the ISS repository, specific warnings related to pharmacokinetic effects have been identified in the label section of 14 drugs. For six drugs on the list, specific therapy modifications (alternative drugs) or dosing adjustments are proposed in existing evidence-based guidelines.